Thymosin Alpha-1 vs AOD-9604: Cost and Access Head-to-Head

What Each Peptide Does and Why Cost Differs

Thymosin alpha-1 and AOD-9604 target entirely separate biological pathways, and that distinction shapes their pricing, sourcing, and regulatory standing. Thymalfasin is a 28-amino-acid peptide that modulates dendritic cell maturation and T-helper cell differentiation. Its clinical history includes trials in chronic hepatitis B, hepatitis C, and as adjunctive immunotherapy in certain cancers 1. Romani et al. documented its capacity for immune restoration across multiple disease states, with particular strength in viral hepatitis populations where interferon response was suboptimal.

AOD-9604 is the C-terminal fragment (amino acids 176 to 191) of human growth hormone. Heffernan et al. showed it stimulates lipolysis in animal models without activating the GH receptor or raising IGF-1 levels 2. That selective lipolytic action made it attractive for obesity research, but a Phase IIb oral formulation trial failed to beat placebo for weight loss in humans, and development stalled.

The cost gap between these peptides reflects manufacturing complexity and regulatory history. Thymalfasin requires a longer synthesis chain and has a documented pharmacopeial monograph, which raises raw-material costs. AOD-9604, a shorter fragment, is cheaper to synthesize. Both reach US patients almost exclusively through 503A and 503B compounding pharmacies since neither holds an active FDA-approved NDA for any indication in the United States.

Thymosin Alpha-1 Pricing Breakdown

A 30-day supply of compounded thymalfasin typically runs between $150 and $400, depending on the pharmacy, dosage form, and prescribed frequency. Standard dosing in clinical literature ranges from 1.6 mg subcutaneous injection two to three times weekly 1. Some US compounding pharmacies package multi-dose vials at 3 mg/mL or 5 mg/mL concentrations, and the per-vial price varies based on fill volume.

Zadaxin, the branded injectable thymalfasin produced by SciClone Pharmaceuticals, received approval in over 30 countries for hepatitis B adjunctive therapy. It was never FDA-approved in the US, and SciClone's operations have since been absorbed by other entities. Patients who obtained Zadaxin internationally paid $800 to $1,200 per month at branded pricing. That option is now essentially unavailable.

The compounding route is the only practical path. Prices from 503B outsourcing facilities tend to cluster around $200 to $300 per month for a standard twice-weekly protocol. Individual 503A pharmacies operating under patient-specific prescriptions may charge more or less depending on state regulations and overhead. Telehealth platforms specializing in peptide therapy have begun listing thymalfasin at fixed monthly rates, often bundling the peptide with a consultation fee in the $250 to $450 range.

Patients should verify that their compounding pharmacy holds current FDA registration as a 503B outsourcing facility or a valid state 503A license. Unregistered suppliers present both safety and legal risks. The FDA has issued multiple warning letters to peptide vendors operating without proper registration since 2023 3.

AOD-9604 Pricing Breakdown

AOD-9604 is generally less expensive per month than thymalfasin. Compounded subcutaneous AOD-9604 from 503B facilities ranges from $100 to $300 for a 30-day supply at typical dosing of 250 to 300 mcg daily. Some clinics use higher doses of 500 mcg daily, which pushes costs toward the upper end.

The peptide's shorter amino acid sequence (16 residues vs. 28 for thymalfasin) keeps synthesis costs lower. Raw AOD-9604 is widely available from peptide manufacturers, which increases supplier competition and drives per-milligram pricing down. A 5 mg vial of lyophilized AOD-9604 from a reputable compounding pharmacy typically costs $60 to $120. At 300 mcg per day, one 5 mg vial lasts roughly 16 days, putting the two-vial monthly cost at $120 to $240.

Oral and sublingual formulations have appeared from some compounding pharmacies, priced at $80 to $180 per month. Bioavailability data for oral AOD-9604 in humans is scarce. The failed Phase IIb trial used an oral formulation and showed no significant weight loss versus placebo, raising questions about whether oral delivery achieves adequate systemic levels 4. Most clinicians prescribing AOD-9604 prefer the subcutaneous route based on the animal data from Heffernan et al. 2.

Research-grade AOD-9604 sold as "for laboratory use only" appears online at dramatically lower prices ($30 to $50 per 5 mg). These products lack the testing, sterility assurance, and chain-of-custody documentation required for human use. The FDA considers selling such products for human injection an unapproved drug violation 3.

Insurance Coverage: Neither Peptide Qualifies

No major US commercial insurer or Medicare Part D plan covers thymosin alpha-1 or AOD-9604. The reason is straightforward: neither holds an active FDA-approved NDA. Insurance formularies require an approved indication to list a drug, and compounded medications are categorically excluded from most pharmacy benefit designs.

Some patients have attempted to obtain thymalfasin coverage through medical-benefit exceptions, citing its approved status in other countries and published trial data in hepatitis B 1. These appeals rarely succeed. A 2022 analysis of prior-authorization denials by the American Academy of Allergy, Asthma & Immunology noted that compounded peptides without US approval face denial rates exceeding 95% across commercial plans 5.

AOD-9604 fares worse in coverage discussions because it lacks approval in any country. Without a single regulatory authority endorsing it for any indication, there is no pathway to argue medical necessity within existing insurance frameworks.

Health savings accounts (HSAs) and flexible spending accounts (FSAs) may cover compounded peptides if prescribed by a licensed provider for a diagnosed medical condition. The IRS requires a Letter of Medical Necessity from the prescriber. Patients using HSA or FSA funds should keep the prescription, compounding pharmacy receipt, and the prescriber's letter together for tax documentation.

Pharmacy Access and Sourcing

Both peptides are available through the same general supply chain: licensed compounding pharmacies operating under FDA Section 503A (patient-specific) or 503B (outsourcing facility) designations. Geographic access varies. States with strong compounding pharmacy sectors, including Florida, Texas, and California, tend to have more suppliers and competitive pricing.

Thymalfasin sourcing requires pharmacies to obtain pharmaceutical-grade thymosin alpha-1 bulk powder from registered suppliers. The number of qualified bulk suppliers is smaller than for AOD-9604, which contributes to thymalfasin's higher price floor. Pharmacies must verify that their bulk thymalfasin meets USP or equivalent purity standards.

AOD-9604 bulk powder is available from a larger pool of peptide synthesis companies. This broader supply base means more 503B facilities stock it. Patients searching for AOD-9604 will typically find it listed by a greater number of telehealth peptide clinics compared to thymalfasin.

Telehealth access has expanded significantly for both peptides since 2023. Multiple platforms now offer remote consultations with licensed prescribers who can evaluate patients and, if appropriate, send prescriptions to partnered compounding pharmacies. Typical telehealth peptide consultation fees range from $99 to $250 for an initial visit, with follow-up appointments at $50 to $150.

Shipping considerations matter. Both peptides require cold-chain shipping when reconstituted. Lyophilized (freeze-dried) vials are more stable and can ship at ambient temperature, but once reconstituted with bacteriostatic water, they need refrigeration and typically arrive via overnight cold-pack shipping at an additional $15 to $35 per order.

Regulatory Standing and Future Access Risk

The regulatory outlook for these two peptides differs in important ways that affect long-term access planning.

Thymalfasin holds a stronger regulatory position. It has been approved in over 30 countries, has a substantial published literature base including randomized controlled trials in hepatitis B and C, and has appeared on the World Health Organization's list of essential medicines in some national formularies. The FDA has not blocked its compounding in the US, and it does not appear on the FDA's "Difficult to Compound" list or the "Demonstrably Difficult to Compound" list as of May 2026. A nominated bulk drug substance application for thymalfasin has been reviewed by the FDA's Pharmacy Compounding Advisory Committee 6.

AOD-9604 sits in a more vulnerable regulatory position. It holds no approval anywhere. Its clinical trial history includes a failed Phase IIb weight-loss trial. The Therapeutic Goods Administration (TGA) in Australia classified AOD-9604 and several related peptides under increased regulatory scrutiny in 2023 7. If the FDA were to add AOD-9604 to its list of substances that cannot be compounded, access would effectively end for US patients.

Patients investing in long-term peptide protocols should weigh this asymmetry. A course of thymalfasin carries lower regulatory disruption risk than a comparable commitment to AOD-9604. Clinicians who prescribe AOD-9604 should counsel patients about the possibility that compounding access could narrow or disappear with a single FDA enforcement action.

Head-to-Head Cost Comparison Table

For a standard 30-day protocol, here is how the two peptides compare across key access and cost metrics:

Monthly peptide cost (compounded, subcutaneous): Thymalfasin $150 to $400 vs. AOD-9604 $100 to $300.

Typical daily dose: Thymalfasin 1.6 mg two to three times per week vs. AOD-9604 250 to 300 mcg daily.

Telehealth consultation (initial): $99 to $250 for either peptide.

Cold-chain shipping: $15 to $35 per order for either peptide when reconstituted.

Insurance coverage probability: Near zero for both.

HSA/FSA eligibility: Yes for both with Letter of Medical Necessity.

Number of 503B facilities stocking: Fewer for thymalfasin, more for AOD-9604.

Regulatory risk level: Lower for thymalfasin (international approvals), higher for AOD-9604 (no approvals anywhere).

Annualized, a thymalfasin protocol runs roughly $1,800 to $4,800 plus consultations. An AOD-9604 protocol runs $1,200 to $3,600 plus consultations. The gap narrows when factoring in consultation fees and shipping, which are similar for both.

Who Should Consider Which Peptide

These peptides are not interchangeable. They target different systems and suit different clinical scenarios.

Thymalfasin fits patients with documented immune dysfunction, chronic viral hepatitis, or those seeking adjunctive immunomodulation under physician supervision. Its evidence base is stronger, its regulatory standing is more secure, and its mechanism of action is well-characterized in peer-reviewed literature 1. The higher monthly cost reflects a more established clinical profile.

AOD-9604 appeals to patients interested in lipolysis support without the metabolic side effects of full-length growth hormone. Its evidence base is thinner. The animal data from Heffernan et al. showed clear lipolytic activity without IGF-1 elevation 2, but human data confirming clinically meaningful fat loss at available doses remains limited. The lower price point reflects both cheaper synthesis and weaker clinical validation.

A patient choosing between these peptides is not choosing between two versions of the same therapy. They are choosing between immune modulation and targeted fat metabolism, between a peptide with international regulatory acceptance and one operating entirely within the compounding gray zone.

Prescribers should document the clinical rationale for either peptide clearly, maintain progress notes with objective markers (immune panels for thymalfasin, body composition measurements for AOD-9604), and re-evaluate the protocol at 90-day intervals. Patients paying $200+ per month out of pocket deserve evidence that the investment is producing measurable results.